News Detail

Novocure Says Optune Pax Receives CE Mark For Treatment Of Adult Patients With Locally Advanced Pancreatic Cancer Of Exocrine Origin, Concomitant With Gem/Nab-Pac

Benzinga · 4d ago

Listen to the news

The CE Mark is supported by results from the Phase 3 PANOVA-3 trial demonstrating a statistically significant improvement in overall survival (OS) for patients treated with Optune Pax concomitant with gemcitabine and nab-paclitaxel

Treatment with Optune Pax was also shown to significantly delay patients’ pain progression, helping to preserve quality of life

Optune Pax is a first-of-its-kind wearable medical device for the treatment of pancreatic cancerthat delivers Tumor Treating Fields, alternating electric fields that cause cancer cell death

Novocure (NASDAQ:NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel (gem/nab-pac) in accordance with guideline recommendations.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.

What's Trending

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.